Humalog Mix75/25
Loading...Humalog Mix75/25 Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Humalog differs from Regular human insulin by its rapid onset of action as well as a shorter duration of activity. Therefore, the dose of Humalog Mix75/25 should be given within 15 minutes before a meal.
Hypoglycemia is the most common adverse effect associated with the use of insulins, including Humalog Mix75/25. As with all insulins, the timing of hypoglycemia may differ among various insulin formulations. Glucose monitoring is recommended for all patients with diabetes.
Any change of insulin should be made cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type (e.g., Regular, NPH, analog), species, or method of manufacture may result in the need for a change in dosage.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Humalog Mix75/25, a mixture of 75% insulin lispro protamine suspension and 25% insulin lispro injection, (rDNA origin), is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia. Humalog Mix75/25 has a more rapid onset of glucose–lowering activity compared with Humulin 70/30 while having a similar duration of action. This profile is achieved by combining the rapid onset of Humalog with the intermediate action of insulin lispro protamine suspension.
History
There is currently no drug history available for this drug.
Other Information
Humalog® Mix75/25™ [75% insulin lispro protamine suspension and 25% insulin lispro injection, (rDNA origin)] is a mixture of insulin lispro solution, a rapid–acting blood glucose–lowering agent and insulin lispro protamine suspension, an intermediate–acting blood glucose–lowering agent. Chemically, insulin lispro is Lys(B28), Pro(B29) human insulin analog, created when the amino acids at positions 28 and 29 on the insulin B–chain are reversed. Insulin lispro is synthesized in a special non–pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered to produce insulin lispro. Insulin lispro protamine suspension (NPL component) is a suspension of crystals produced from combining insulin lispro and protamine sulfate under appropriate conditions for crystal formation.
Insulin lispro has the following primary structure:
Insulin lispro has the empirical formula C257H383N65O77S6 and a molecular weight of 5808, both identical to that of human insulin.
Humalog Mix75/25 vials and Pens contain a sterile suspension of insulin lispro protamine suspension mixed with soluble insulin lispro for use as an injection.
Each milliliter of Humalog Mix75/25 injection contains insulin lispro 100 units, 0.28 mg protamine sulfate, 16 mg glycerin, 3.78 mg dibasic sodium phosphate, 1.76 mg Metacresol, zinc oxide content adjusted to provide 0.025 mg zinc ion, 0.715 mg phenol, and Water for Injection. Humalog Mix75/25 has a pH of 7.0 to 7.8. Hydrochloric acid 10% and/or sodium hydroxide 10% may have been added to adjust pH.
Sources
Humalog Mix75/25 Manufacturers
-
Physicians Total Care, Inc.
![Humalog Mix75/25 (Insulin Lispro) Injection, Suspension [Physicians Total Care, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Humalog Mix75/25 | Physicians Total Care, Inc.
Table 1: Summary of Pharmacodynamic Properties of Insulin Products (Pooled Cross-Study Comparison)Insulin Products
Dose, U/kg
Time of Peak Activity, Hours After Dosing
Percent of Total Activity Occurring in the First 4 Hours
Humalog
0.3
2.4
(0.8 – 4.3)70%
(49 – 89%)Humulin R
0.32
(0.26 – 0.37)4.4
(4.0 – 5.5)54%
(38 – 65%)Humalog Mix75/25
0.3
2.6
(1.0 – 6.5)35%
(21 – 56%)Humulin 70/30
0.3
4.4
(1.5 – 16)32%
(14 – 60%)Humalog Mix50/50
0.3
2.3
(0.8 – 4.8)45%
(27 – 69%)Humulin 50/50
0.3
3.3
(2.0 – 5.5)44%
(21 – 60%)NPH
0.32
(0.27 – 0.40)5.5
(3.5 – 9.5)14%
(3.0 – 48%)NPL component
0.3
5.8
(1.3 – 18.3)22%
(6.3 – 40%)Humalog Mix75/25 is intended only for subcutaneous administration. Humalog Mix75/25 should not be administered intravenously. Dosage regimens of Humalog Mix75/25 will vary among patients and should be determined by the healthcare provider familiar with the patient’s metabolic needs, eating habits, and other lifestyle variables. Humalog has been shown to be equipotent to Regular human insulin on a molar basis. One unit of Humalog has the same glucose–lowering effect as one unit of Regular human insulin, but its effect is more rapid and of shorter duration. Humalog Mix75/25 has a similar glucose–lowering effect as compared with Humulin 70/30 on a unit for unit basis. The quicker glucose–lowering effect of Humalog is related to the more rapid absorption rate of insulin lispro from subcutaneous tissue.
Humalog Mix75/25 starts lowering blood glucose more quickly than Regular human insulin, allowing for convenient dosing immediately before a meal (within 15 minutes). In contrast, mixtures containing Regular human insulin should be given 30 to 60 minutes before a meal.
The rate of insulin absorption and consequently the onset of activity are known to be affected by the site of injection, exercise, and other variables. As with all insulin preparations, the time course of action of Humalog Mix75/25 may vary considerably in different individuals or within the same individual. Patients must be educated to use proper injection techniques.
Humalog Mix75/25 should be inspected visually before use. Humalog Mix75/25 should be used only if it appears uniformly cloudy after mixing. Humalog Mix75/25 should not be used after its expiration date.
-
Eli Lilly And Company
Humalog Mix75/25 |
Table 1*: Summary of Pharmacodynamic Properties of Insulin Products (Pooled Cross-Study Comparison)* The information supplied in Table 1 indicates when peak insulin activity can be expected and the percent of the total insulin activity occurring during the first 4 hours. The information was derived from 3 separate glucose clamp studies in nondiabetic subjects. Values represent means, with ranges provided in parentheses.
Insulin Products Dose, U/kg Time of Peak Activity, Hours After Dosing Percent of Total Activity Occurring in the First 4 Hours Humalog 0.3 2.4
(0.8 - 4.3) 70%
(49 - 89%) Humulin R 0.32
(0.26 - 0.37) 4.4
(4.0 - 5.5) 54%
(38 - 65%) Humalog Mix75/25 0.3 2.6
(1.0 - 6.5) 35%
(21 - 56%) Humulin 70/30 0.3 4.4
(1.5 - 16) 32%
(14 - 60%) Humalog Mix50/50 0.3 2.3
(0.8 - 4.8) 45%
(27 - 69%) Humulin 50/50 0.3 3.3
(2.0 - 5.5) 44%
(21 - 60%) NPH 0.32
(0.27 - 0.40) 5.5
(3.5 - 9.5) 14%
(3.0 - 48%) NPL component 0.3 5.8
(1.3 - 18.3) 22%
(6.3 - 40%)Humalog Mix75/25 is intended only for subcutaneous administration. Humalog Mix75/25 should not be administered intravenously. Dosage regimens of Humalog Mix75/25 will vary among patients and should be determined by the healthcare provider familiar with the patient's metabolic needs, eating habits, and other lifestyle variables. Humalog has been shown to be equipotent to Regular human insulin on a molar basis. One unit of Humalog has the same glucose-lowering effect as one unit of Regular human insulin, but its effect is more rapid and of shorter duration. Humalog Mix75/25 has a similar glucose-lowering effect as compared with Humulin 70/30 on a unit for unit basis. The quicker glucose-lowering effect of Humalog is related to the more rapid absorption rate of insulin lispro from subcutaneous tissue.
Humalog Mix75/25 starts lowering blood glucose more quickly than Regular human insulin, allowing for convenient dosing immediately before a meal (within 15 minutes). In contrast, mixtures containing Regular human insulin should be given 30 to 60 minutes before a meal.
The rate of insulin absorption and consequently the onset of activity are known to be affected by the site of injection, exercise, and other variables. As with all insulin preparations, the time course of action of Humalog Mix75/25 may vary considerably in different individuals or within the same individual. Patients must be educated to use proper injection techniques.
Humalog Mix75/25 should be inspected visually before use. Humalog Mix75/25 should be used only if it appears uniformly cloudy after mixing. Humalog Mix75/25 should not be used after its expiration date.
![Humalog Mix75/25 (Insulin Lispro) Injection, Suspension Humalog Mix75/25 Kwikpen (Insulin Lispro) Injection, Suspension [Eli Lilly And Company
]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c73da51a-1899-45ad-b6cf-9c52c36a25dd&name=humalogmix75-pen-carton-NL012-01.jpg)
Login To Your Free Account